Immuno-modulating properties of saliphenylhalamide, SNS-032, obatoclax, and gemcitabine

Antiviral Research

Volumn 126, Issue , 2016, Pages 69-80

  Söderholm, Sandra ^a,b   Anastasina, Maria ^c   Islam, Mohammad Majharul ^c   Tynell, Janne ^d   Poranen, Minna M ^c   Bamford, Dennis H ^a,c   Stenman, Jakob ^e   Julkunen, Ilkka ^d,f   Šauliene, Ingrida ^g   De Brabander, Jef K ^h   Matikainen, Sampsa ^b   Nyman, Tuula A ^a   Saelens, Xavier ^i,j   Kainov, Denis ^c,f  

^a UNIVERSITY OF HELSINKI   (Finland)

^b FINNISH INSTITUTE OF OCCUPATIONAL HEALTH   (Finland)

^c UNIVERSITY OF HELSINKI   (Finland)

^d NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^e MINERVA FOUNDATION INSTITUTE FOR MEDICAL RESEARCH   (Finland)

^f UNIVERSITY OF TURKU   (Finland)

^g IAULIAI UNIVERSITY   (Lithuania)

^h UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

ⁱ DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^j GHENT UNIVERSITY   (Belgium)

more..

Author keywords

Antiviral agents; Immune responses; Influenza A virus; Innate immunity; Virus host interaction

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; GEMCITABINE; HEAT SHOCK PROTEIN 27; IMMUNOMODULATING AGENT; INTERFERON REGULATORY FACTOR 3; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; N [5 (5 TERT BUTYL 2 OXAZOLYLMETHYLTHIO) 2 THIAZOLYL]ISONIPECOTAMIDE; OBATOCLAX; PROTEIN C JUN; PROTEIN KINASE B; SALIPHENYLHALAMIDE; UNCLASSIFIED DRUG; AMIDE; ANTINEOPLASTIC AGENT; CYTOKINE; DEOXYCYTIDINE; IMMUNOLOGIC FACTOR; LIPOPOLYSACCHARIDE; N-(5-(((5-(1,1-DIMETHYLETHYL)-2-OXAZOLYL)METHYL)THIO)-2-THIAZOLYL)-4-PIPERIDINECARBOXAMIDE; OXAZOLE DERIVATIVE; PHOSPHOPROTEIN; PYRROLE DERIVATIVE; SALICYLIC ACID DERIVATIVE; THIAZOLE DERIVATIVE; VIRUS RNA;

ARTICLE; AUTORADIOGRAPHY; DRUG EFFECT; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOBLOTTING; IMMUNOMODULATION; INFLUENZA A; INFLUENZA A VIRUS; INNATE IMMUNITY; MACROPHAGE ACTIVATION; NONHUMAN; NORMAL HUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; VIRUS IMMUNITY; VIRUS REPLICATION; VIRUS STRAIN; ANALOGS AND DERIVATIVES; BIOSYNTHESIS; CELL CULTURE; COINFECTION; DRUG EFFECTS; IMMUNOLOGY; INFLUENZA, HUMAN; MACROPHAGE; METABOLISM; PHYSIOLOGY; VIROLOGY;

AMIDES; ANTINEOPLASTIC AGENTS; ANTIVIRAL AGENTS; CELLS, CULTURED; COINFECTION; CYTOKINES; DEOXYCYTIDINE; HUMANS; IMMUNITY, INNATE; IMMUNOLOGIC FACTORS; INFLUENZA A VIRUS; INFLUENZA, HUMAN; INTERFERON-ALPHA; LIPOPOLYSACCHARIDES; MACROPHAGES; OXAZOLES; PHOSPHOPROTEINS; PYRROLES; RNA, VIRAL; SALICYLATES; THIAZOLES; VIRUS REPLICATION;

EID: 84952845480     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2015.12.011     Document Type: Article

References (65)

1. M. Anastasina, and et al. The C terminus of NS1 protein of influenza A/WSN/1933(H1N1) virus modulates antiviral responses in infected human macrophages and mice J. Gen. Virol. 96 2015 2086 2091 10.1099/vir.0.000171
2. N. Bajwa, and et al. Inhibitors of the anti-apoptotic Bcl-2 proteins: a patent review Expert Opin. Ther. Pat. 22 2012 37 55 10.1517/13543776.2012.644274
3. I. Banerjee, and et al. Influenza A virus uses the aggresome processing machinery for host cell entry Science 346 2014 473 477 10.1126/science.1257037
4. L.B. Beach, and et al. Novel inhibitors of human immunodeficiency virus type 2 infectivity J. Gen. Virol. 95 2014 2778 2783 10.1099/vir.0.069864-0
5. A. Benedict, and et al. Repurposing FDA-approved drugs as therapeutics to treat Rift Valley fever virus infection Front. Microbiol. 6 2015 676 10.3389/fmicb.2015.00676
6. Y. Borgeling, and et al. Inhibition of p38 mitogen-activated protein kinase impairs influenza virus-induced primary and secondary host gene responses and protects mice from lethal H5N1 infection J. Biol. Chem. 289 2014 13 27 10.1074/jbc.M113.469239
7. Z. Cao, and et al. The epitope and neutralization mechanism of AVFluIgG01, a broad-reactive human monoclonal antibody against H5N1 influenza virus PLoS One 7 2012 e38126 10.1371/journal.pone.0038126
8. K. Chairat, and et al. Pharmacokinetic properties of anti-influenza neuraminidase inhibitors J. Clin. Pharmacol. 53 2013 119 139 10.1177/0091270012440280
9. G. Chase, and et al. Hsp90 inhibitors reduce influenza virus replication in cell culture Virology 377 2008 431 439 10.1016/j.virol.2008.04.040
10. C. Cianci, and et al. Influenza nucleoprotein: promising target for antiviral chemotherapy Antivir. Chem. Chemother. 23 2013 77 91 10.3851/IMP2235
11. M.P. Clark, and et al. Discovery of a novel, first-in-class, orally bioavailable azaindole inhibitor (VX-787) of influenza PB2 J. Med. Chem. 57 2014 6668 6678 10.1021/jm5007275
12. C.C. Colpitts, and et al. A small molecule inhibits virion attachment to heparan sulfate- or sialic acid-containing glycans J. Virol. 88 2014 7806 7817 10.1128/JVI.00896-14
13. P. Das, and et al. SAR based optimization of a 4-Quinoline carboxylic acid analog with potent anti-viral activity ACS Med. Chem. Lett. 4 2013 517 521 10.1021/ml300464h
14. O.V. Denisova, and et al. Obatoclax, saliphenylhalamide, and gemcitabine inhibit influenza a virus infection J. Biol. Chem. 287 2012 35324 35332 10.1074/jbc.M112.392142
15. O.V. Denisova, and et al. Akt inhibitor MK2206 prevents influenza pH1N1 virus infection in vitro Antimicrob. Agents Chemother. 58 2014 3689 3696 10.1128/AAC.02798-13
16. N.R. Donelan, and et al. A recombinant influenza A virus expressing an RNA-binding-defective NS1 protein induces high levels of beta interferon and is attenuated in mice J. Virol. 77 2003 13257 13266
17. K. Droebner, and et al. Role of hypercytokinemia in NF-kappaB p50-deficient mice after H5N1 influenza A virus infection J. Virol. 82 2008 11461 11466 10.1128/JVI.01071-08
18. T.O. Edinger, and et al. Entry of influenza A virus: host factors and antiviral targets J. Gen. Virol. 95 2014 263 277 10.1099/vir.0.059477-0
19. J.M. Ferdinands, and et al. A pilot study of host genetic variants associated with influenza-associated deaths among children and young adults Emerg. Infect. Dis. 17 2011 2294 2302 10.3201/eid1712.111002
20. Y. Fujioka, and et al. The Ras-PI3K signaling pathway is involved in clathrin-independent endocytosis and the internalization of influenza viruses PLoS One 6 2011 e16324 10.1371/journal.pone.0016324
21. Y. Furuta, and et al. T-705 (favipiravir) and related compounds: novel broad-spectrum inhibitors of RNA viral infections Antivir. Res. 82 2009 95 102 10.1016/j.antiviral.2009.02.198
22. D.S. Gesto, and et al. Gemcitabine: a critical nucleoside for cancer therapy Curr. Med. Chem. 19 2012 1076 1087
23. E.S. Gold, and et al. 25-Hydroxycholesterol acts as an amplifier of inflammatory signaling Proc. Natl. Acad. Sci. U. S. A. 111 2014 10666 10671 10.1073/pnas.1404271111
24. A.C. Graham, and et al. Mast cells and influenza a virus: association with allergic responses and beyond Front. Immunol. 6 2015 238 10.3389/fimmu.2015.00238
25. E. Hoffmann, and et al. A DNA transfection system for generation of influenza A virus from eight plasmids Proc. Natl. Acad. Sci. U. S. A. 97 2000 6108 6113 10.1073/pnas.100133697
26. A.C. Hurt The epidemiology and spread of drug resistant human influenza viruses Curr. Opin. Virol. 8 2014 22 29 10.1016/j.coviro.2014.04.009
27. S.J. James, and et al. MAPK phosphatase 5 expression induced by influenza and other RNA virus infection negatively regulates IRF3 activation and type I interferon response Cell Rep. 10 10 2015 1722 1734 10.1016/j.celrep.2015.02.030
28. M. Jiang, and et al. MAP kinase p38alpha regulates type III interferon (IFN-lambda1) gene expression in human monocyte-derived dendritic cells in response to RNA stimulation J. Leukoc. Biol. 97 2015 307 320 10.1189/jlb.2A0114-059RR
29. C. Joseph, and et al. Bacterial and viral infections associated with influenza Influenza Other Respir. Viruses 7 Suppl. 2 2013 105 113 10.1111/irv.12089
30. L. Kakkola, and et al. Anticancer compound ABT-263 accelerates apoptosis in virus-infected cells and imbalances cytokine production and lowers survival rates of infected mice Cell Death Dis. 4 2013 e742 10.1038/cddis.2013.267
31. M.G. Katze, and et al. Viruses and interferon: a fight for supremacy Nat. Rev. Immunol. 2 2002 675 687 10.1038/nri888
32. R.M. Krug Functions of the influenza A virus NS1 protein in antiviral defense Curr. Opin. Virol. 12 2015 1 6 10.1016/j.coviro.2015.01.007
33. S. Lebreton, and et al. Evaluating the potential of vacuolar ATPase inhibitors as anticancer agents and multigram synthesis of the potent salicylihalamide analog saliphenylhalamide Bioorg Med. Chem. Lett. 18 2008 5879 5883 10.1016/j.bmcl.2008.07.003
34. A. Loregian, and et al. Antiviral strategies against influenza virus: towards new therapeutic approaches Cell Mol. Life Sci. 71 2014 3659 3683 10.1007/s00018-014-1615-2
35. Y. Lu, and et al. Peptidomimetic furin inhibitor MI-701 in combination with oseltamivir and ribavirin efficiently blocks propagation of highly pathogenic avian influenza viruses and delays high level oseltamivir resistance in MDCK cells Antivir. Res. 120 2015 89 100 10.1016/j.antiviral.2015.05.006
36. M.A. Mata, and et al. Chemical inhibition of RNA viruses reveals REDD1 as a host defense factor Nat. Chem. Biol. 7 2011 712 719 10.1038/nchembio.645
37. M. Matsumoto, and et al. TLR3: interferon induction by double-stranded RNA including poly(I: C) Adv. Drug Deliv. Rev. 60 2008 805 812 10.1016/j.addr.2007.11.005
38. S.I. Miller, and et al. LPS, TLR4 and infectious disease diversity Nat. Rev. Microbiol. 3 2005 36 46 10.1038/nrmicro1068
39. J.Y. Min, and et al. The primary function of RNA binding by the influenza A virus NS1 protein in infected cells: Inhibiting the 2'-5' oligo (A) synthetase/RNase L pathway Proc. Natl. Acad. Sci. U. S. A. 103 2006 7100 7105 10.1073/pnas.0602184103
40. M. Morita, and et al. The lipid mediator protectin D1 inhibits influenza virus replication and improves severe influenza Cell 153 2013 112 125 10.1016/j.cell.2013.02.027
41. K.H. Muller, and et al. The proton translocation domain of cellular vacuolar ATPase provides a target for the treatment of influenza A virus infections Br. J. Pharmacol. 164 2011 344 357 10.1111/j.1476-5381.2011.01346.x
42. K.H. Muller, and et al. Emerging cellular targets for influenza antiviral agents Trends Pharmacol. Sci. 33 2012 89 99 10.1016/j.tips.2011.10.004
43. S.G. Muthuri, and et al. Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data Lancet Respir. Med. 2 2014 395 404 10.1016/S2213-2600(14)70041-4
44. C.M. Newby, and et al. The RNA binding domain of influenza A virus NS1 protein affects secretion of tumor necrosis factor alpha, interleukin-6, and interferon in primary murine tracheal epithelial cells J. Virol. 81 2007 9469 9480 10.1128/JVI.00989-07
45. M.Q. Nicol, and et al. A novel family of peptides with potent activity against influenza A viruses J. Gen. Virol. 93 2012 980 986 10.1099/vir.0.038679-0
46. L. O'Mahony, and et al. Regulation of the immune response and inflammation by histamine and histamine receptors J. Allergy Clin. Immunol. 128 2011 1153 1162 10.1016/j.jaci.2011.06.051
47. M.B. Ortigoza, and et al. A novel small molecule inhibitor of influenza A viruses that targets polymerase function and indirectly induces interferon PLoS Pathog. 8 2012 e1002668 10.1371/journal.ppat.1002668
48. E. Ortiz-Riano, and et al. Inhibition of arenavirus by A3, a pyrimidine biosynthesis inhibitor J. Virol. 88 2014 878 889 10.1128/JVI.02275-13
49. S. Pautus, and et al. New 7-methylguanine derivatives targeting the influenza polymerase PB2 cap-binding domain J. Med. Chem. 56 2013 8915 8930 10.1021/jm401369y
50. O. Perwitasari, and et al. Verdinexor, a novel selective inhibitor of nuclear export, reduces influenza a virus replication in vitro and in vivo J. Virol. 88 2014 10228 10243 10.1128/JVI.01774-14
51. O. Perwitasari, and et al. Repurposing kinase inhibitors as antiviral agents to control influenza a virus replication Assay. Drug Dev. Technol. 2015 10.1089/adt.2015.0003.drrr
52. J. Pirhonen, and et al. Virus infection activates IL-1 beta and IL-18 production in human macrophages by a caspase-1-dependent pathway J. Immunol. 162 1999 7322 7329
53. R.E. Randall, and et al. Interferons and viruses: an interplay between induction, signalling, antiviral responses and virus countermeasures J. Gen. Virol. 89 2008 1 47 10.1099/vir.0.83391-0
54. A. Romanovskaya, and et al. High-throughput purification of double-stranded RNA molecules using convective interaction media monolithic anion exchange columns J. Chromatogr. A 1278 2013 54 60 10.1016/j.chroma.2012.12.050
55. A.J. Sadler, and et al. Interferon-inducible antiviral effectors Nat. Rev. Immunol. 8 2008 559 568 10.1038/nri2314
56. K.R. Short, and et al. The fate of influenza A virus after infection of human macrophages and dendritic cells J. Gen. Virol. 93 2012 2315 2325 10.1099/vir.0.045021-0
57. D.F. Smee, and et al. D282, a non-nucleoside inhibitor of influenza virus infection that interferes with de novo pyrimidine biosynthesis Antivir. Chem. Chemother. 22 2012 263 272 10.3851/IMP2105
58. W.G. Tong, and et al. Phase I and pharmacologic study of SNS-032, a potent and selective Cdk2, 7, and 9 inhibitor, in patients with advanced chronic lymphocytic leukemia and multiple myeloma J. Clin. Oncol. 28 2010 3015 3022 10.1200/JCO.2009.26.1347
59. E. Vanderlinden, and et al. Emerging antiviral strategies to interfere with influenza virus entry Med. Res. Rev. 34 2014 301 339 10.1002/med.21289
60. V. Veckman, and et al. TNF-alpha and IFN-alpha enhance influenza-A-virus-induced chemokine gene expression in human A549 lung epithelial cells Virology 345 2006 96 104 10.1016/j.virol.2005.09.043
61. M.P. Walkiewicz, and et al. Novel inhibitor of influenza non-structural protein 1 blocks multi-cycle replication in an RNase L-dependent manner J. Gen. Virol. 92 2011 60 70 10.1099/vir.0.025015-0
62. Y. Wu, and et al. Flipping in the pore: discovery of dual inhibitors that bind in different orientations to the wild-type versus the amantadine-resistant S31N mutant of the influenza A virus M2 proton channel J. Am. Chem. Soc. 136 2014 17987 17995 10.1021/ja508461m
63. M. Zambon Developments in the treatment of severe influenza: lessons from the pandemic of 2009 and new prospects for therapy Curr. Opin. Infect. Dis. 27 2014 560 565 10.1097/QCO.0000000000000113
64. M. Zanin, and et al. An anti-H5N1 influenza virus FcDART antibody is a highly efficacious therapeutic agent and prophylactic against H5N1 influenza virus infection J. Virol. 89 2015 4549 4561 10.1128/JVI.00078-15
65. L. Zhang, and et al. Inhibition of pyrimidine synthesis reverses viral virulence factor-mediated block of mRNA nuclear export J. Cell Biol. 196 2012 315 326 10.1083/jcb.201107058